HNP [HUANENG POWER INTERNATIONAL] 20-F: _______________________ FORM 20-F (Mark One) ¨ OR þ

[_______________________ FORM 20-F (Mark One) ¨ OR þ OR ¨ OR ¨ Date of event requiring this shell company report For the transaction period form _______to ______________ HUANENG POWER INTERNATIONAL, INC. PEOPLE’S REPUBLIC OF CHINA (Jurisdiction of incorporation or organization) HUANENG BUILDING 6 FUXINGMENNEI STREET, XICHENG DISTRICT, BEIJING, PEOPLE’S REPUBLIC OF CHINA Mr. Du Daming HUANENG BUILDING, 6 FUXINGMENNEI STREET,] [Articles of Association of Huaneng Power International, Inc. Chapter 1 Article 1 Opinions on Standards for Joint Stock Limited Companies Company Law of the People's Republic of China Securities Law of the People's Republic of China Special Regulations on the Overseas Offering and Listing of Shares by Joint Stock Limited Companies promulgated by the State Council Mandatory Provisions for the] [List of Subsidiaries A list of Huaneng Power International Inc.'s subsidiaries is provided in Note 9 to the consolidated financial statements included in this annual report following Item 19.] [CERTIFICATION I, Cao Peixi, certify that: 1. I have reviewed this annual report on Form 20-F of Huaneng Power International, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [CERTIFICATION I, Zhou Hui, certify that: 1. I have reviewed this annual report on Form 20-F of Huaneng Power International, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [18 U.S.C. Section 1350, Section 906 of the Sarbanes-Oxley Act of 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. EX-13.1 6 ex13-1.htm CERTIFICATION]

By | 2016-03-21T11:04:10+00:00 April 16th, 2015|Categories: Chinese Stocks, HNP, Webplus ver|Tags: , , , , , |0 Comments

MR [Mindray Medical International] IRANNOTICE: Iran Notice Re: Notice of Disclosure Filed in

[Iran Notice Re: Notice of Disclosure Filed in Annual Report on Form 20-F Under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act 100 F Street, N.E. Dear Sirs: Sincerely yours, Alex Lung Chief Financial Officer IRANNOTICE 1 v406536_iran.htm IRANNOTICE]

MR [Mindray Medical International] 20-F: (Original Filing)

[Table of Contents INTRODUCTION 3 PART I. 4 ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 4 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 4 ITEM 3. KEY INFORMATION 4 ITEM 4. INFORMATION ON THE COMPANY 32 ITEM 4A. UNRESOLVED STAFF COMMENTS 54 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 54 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES] [Country of Name of Company Incorporation and Operation Shareholding Principal Activities Shenzhen Mindray Bio-Medical Electronics Co., Ltd. PRC MR Investments (HK) Limited: 88.918828% MR Holdings (HK) Limited: 11.081086% Non-controlling interest:0.000087%* Manufacturing and sales of medical equipment, research and development of related products and investment holding Shenzhen Mindray Investment & Development Co., Ltd. PRC Shenzhen Mindray Bio-Medical Electronics Co., Ltd.:99% Nanjing] [CERTIFICATION I, Li Xiting, certify that: 1. I have reviewed this annual report on Form 20-F of Mindray Medical International Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [CERTIFICATION I, Cheng Minghe, certify that: 1. I have reviewed this annual report on Form 20-F of Mindray Medical International Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [CERTIFICATION I, Alex Lung, certify that: 1. I have reviewed this annual report on Form 20-F of Mindray Medical International Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [CERTIFICATION Li Xiting Executive Chairman of the Board of Directors, President and Co-Chief Executive Officer Cheng Minghe Co-Chief Executive Officer and Chief Strategic Officer Alex Lung Chief Financial Officer] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-178896) of Mindray Medical International Limited of our report dated April 16, 2015 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 20-F. We also consent to]

MR [Mindray Medical International] 20-F: Table of Contents INTRODUCTION 3 PART I. 4

[Table of Contents INTRODUCTION 3 PART I. 4 ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 4 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 4 ITEM 3. KEY INFORMATION 4 ITEM 4. INFORMATION ON THE COMPANY 32 ITEM 4A. UNRESOLVED STAFF COMMENTS 54 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 54 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES] [Country of Name of Company Incorporation and Operation Shareholding Principal Activities Shenzhen Mindray Bio-Medical Electronics Co., Ltd. PRC MR Investments (HK) Limited: 88.918828% MR Holdings (HK) Limited: 11.081086% Non-controlling interest:0.000087%* Manufacturing and sales of medical equipment, research and development of related products and investment holding Shenzhen Mindray Investment & Development Co., Ltd. PRC Shenzhen Mindray Bio-Medical Electronics Co., Ltd.:99% Nanjing] [CERTIFICATION I, Li Xiting, certify that: 1. I have reviewed this annual report on Form 20-F of Mindray Medical International Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [CERTIFICATION I, Cheng Minghe, certify that: 1. I have reviewed this annual report on Form 20-F of Mindray Medical International Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [CERTIFICATION I, Alex Lung, certify that: 1. I have reviewed this annual report on Form 20-F of Mindray Medical International Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [CERTIFICATION Li Xiting Executive Chairman of the Board of Directors, President and Co-Chief Executive Officer Cheng Minghe Co-Chief Executive Officer and Chief Strategic Officer Alex Lung Chief Financial Officer] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-178896) of Mindray Medical International Limited of our report dated April 16, 2015 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 20-F. We also consent to]

CBPO [China Biologic Products] 8-K: (Original Filing)

[Cooperation Agreement on Transfer of Source Plasma and Plasma Ingredients I+II+III Sediments for Producing Blood Products This Agreement is entered into in the city of Beijing on September 30, 2014 by and between: Party A (Supplier): Xinjiang Deyuan Bioengineering Co., Ltd. Party B (Receiver): Guizhou Taibang Biological Products Co., Ltd. WHEREAS: PRC 1. Both parties are established in good standing] [Supplemental Agreement to Cooperation Agreement on Transfer of Source Plasma and Plasma Ingredients I+II+III Sediments for Producing Blood Products This Supplemental Agreement is entered into on April 16, 2015 by and between: Party A (Supplier): Xinjiang Deyuan Bioengineering Co., Ltd; Party B (Receiver): Guizhou Taibang Biological Products Co., Ltd Any term not otherwise defined herein shall have the meaning ascribed] [FOR RELEASE April 16, 2015 China Biologic Receives Approval to Purchase Raw Materials BEIJING, China – April 16, 2015 – These raw materials are expected to be delivered during the second quarter of 2015, and the final purchase volume is contingent upon the Company's quality inspection of these raw materials. The Company expects that the final products made from such] []

CNET [ChinaNet Online] 8-K: (Original Filing)

[ChinaNet Online Holdings Reports Fiscal Year 2014 Financial Results Management to Host Earnings Conference Call on Friday, April 17th at 8:30 am ET BEIJING, April 16, 2015 (GLOBE NEWSWIRE) -- ChinaNet Online Holdings, Inc. (Nasdaq:CNET) ("ChinaNet" or the "Company"), a leading B2B (business to business) Internet technology company providing online-to-offline (O2O) sales channel expansion services for small and medium-sized enterprises] [Item 2.02. Results of Operations and Financial Condition. On April 16 No. Description 99.1 Press Release dated April 16, 2015.]

By | 2016-03-29T22:03:07+00:00 April 16th, 2015|Categories: Chinese Stocks, CNET, SEC Original|Tags: , , , , , |0 Comments

TSM [TAIWAN SEMICONDUCTOR MANUFACTURING CO] 6-K: (Original Filing)

[Taiwan Semiconductor Manufacturing Company Ltd. By Lora Ho Senior Vice President & Chief Financial Officer TSMC Reports First Quarter EPS of NT$3.05 Hsinchu, Taiwan, R.O.C., April 16, 2015 — Year-over-year, first quarter revenue increased 49.8% while net income and diluted EPS both increased 65.0%. Compared to fourth quarter 2014, first quarter results represent a 0.2% decrease in revenue, a 1.2%]

By | 2016-03-12T15:09:34+00:00 April 16th, 2015|Categories: Chinese Stocks, SEC Original, TSM|Tags: , , , , , |0 Comments

CBPO [China Biologic Products] 8-K: Cooperation Agreement on Transfer of Source Plasma and

[Cooperation Agreement on Transfer of Source Plasma and Plasma Ingredients I+II+III Sediments for Producing Blood Products This Agreement is entered into in the city of Beijing on September 30, 2014 by and between: Party A (Supplier): Xinjiang Deyuan Bioengineering Co., Ltd. Party B (Receiver): Guizhou Taibang Biological Products Co., Ltd. WHEREAS: PRC 1. Both parties are established in good standing] [Supplemental Agreement to Cooperation Agreement on Transfer of Source Plasma and Plasma Ingredients I+II+III Sediments for Producing Blood Products This Supplemental Agreement is entered into on April 16, 2015 by and between: Party A (Supplier): Xinjiang Deyuan Bioengineering Co., Ltd; Party B (Receiver): Guizhou Taibang Biological Products Co., Ltd Any term not otherwise defined herein shall have the meaning ascribed] [FOR RELEASE April 16, 2015 China Biologic Receives Approval to Purchase Raw Materials BEIJING, China – April 16, 2015 – These raw materials are expected to be delivered during the second quarter of 2015, and the final purchase volume is contingent upon the Company's quality inspection of these raw materials. The Company expects that the final products made from such] []

Skip to toolbar